{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:11:28Z","timestamp":1790611888180,"version":"4.1.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","award":["R501-LR-RND003-0001458-0000"],"award-info":[{"award-number":["R501-LR-RND003-0001458-0000"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition but remains non-curative and requires lifelong adherence. Rare cases of long-term remission following stem cell transplantation (SCT) have demonstrated the possibility of viral eradication, yet this approach is not scalable or safe for global implementation. A unique subset of people living with HIV, known as elite controllers (ECs), can naturally suppress replication-competent HIV without ART, often for decades, while maintaining stable CD4\u2009+\u2009T cell counts and showing no signs of disease progression. Their ability to sustain treatment-free viral suppression provides compelling evidence that durable remission is biologically achievable, offering a model for cure research. This review synthesizes current evidence on the biology of ECs, encompassing viral, intrinsic antiviral, genetic, and immune mechanisms that underlie natural control. It also examines demographic and clinical characteristics, landmark case reports, and the broader public health implications of elite control. Finally, insights from EC biology are discussed in relation to translational strategies such as gene editing, immune modulation, therapeutic vaccination, and reservoir-targeting approaches designed to mimic or reinforce natural control mechanisms. Understanding the determinants of viral suppression in ECs provides a biological blueprint for the development of a functional cure. As the field advances toward scalable, safe, and durable remission strategies, lessons from ECs remain central to achieving long-term viral control and ultimately ending the HIV epidemic.<\/jats:p>","DOI":"10.1186\/s12985-025-03042-9","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:24:26Z","timestamp":1766568266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Learning from nature: HIV elite controllers as blueprints for a functional cure"],"prefix":"10.1186","volume":"23","author":[{"given":"V.","family":"Kalidasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumitaa","family":"Theva Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"3042_CR1","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/S0140-6736(21)01167-3","volume":"397","author":"C Beyrer","year":"2021","unstructured":"Beyrer C. A pandemic anniversary: 40 years of HIV\/AIDS. Lancet. 2021;397:2142\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(21)01167-3.","journal-title":"Lancet"},{"key":"3042_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nrmicro3132","volume":"11","author":"F Barr\u00e9-Sinoussi","year":"2013","unstructured":"Barr\u00e9-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013;11:877\u201383. https:\/\/doi.org\/10.1038\/nrmicro3132.","journal-title":"Nat Rev Microbiol"},{"key":"3042_CR3","doi-asserted-by":"publisher","unstructured":"Pitman MC, Lau JSY, McMahon JH, Lewin SR. Barriers and strategies to achieve a cure for HIV. Lancet HIV [Internet]. 2018;5:e317\u201328. Available from: https:\/\/doi.org\/10.1016\/S2352-3018(18)30039-0.","DOI":"10.1016\/S2352-3018(18)30039-0"},{"key":"3042_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6096134","author":"W Xu","year":"2017","unstructured":"Xu W, Li H, Wang Q, Hua C, Zhang H, Li W, et al. Advancements in developing strategies for sterilizing and functional HIV cures. Biomed Res Int. 2017. https:\/\/doi.org\/10.1155\/2017\/6096134.","journal-title":"Biomed Res Int"},{"key":"3042_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.20411\/pai.v1i1.133","volume":"1","author":"MM Lederman","year":"2016","unstructured":"Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, et al. A cure for HIV infection: \u201cnot in my lifetime\u201d or \u201cjust around the corner\u201d? Pathog Immun. 2016;1:154\u201364. https:\/\/doi.org\/10.20411\/pai.v1i1.133.","journal-title":"Pathog Immun"},{"key":"3042_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/COH.0b013e328340ffa6","volume":"6","author":"DD Richman","year":"2011","unstructured":"Richman DD. Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS. 2011;6:1\u20133. https:\/\/doi.org\/10.1097\/COH.0b013e328340ffa6.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR7","unstructured":"Joint United Nations Programme on HIV and AIDS, Data Book UNAIDS. 2023. Glob. HIV AIDS Stat. \u2014 Fact sheet. 2023. pp. 1\u2013436. https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"3042_CR8","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, et al. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med. 2021;27:2085\u201398. https:\/\/doi.org\/10.1038\/s41591-021-01590-5.","journal-title":"Nat Med"},{"key":"3042_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.it.2021.12.001","volume":"43","author":"MG Netea","year":"2022","unstructured":"Netea MG, Dom\u00ednguez-Andr\u00e9s J, van de Veerdonk FL, van Crevel R, Pulendran B, van der Meer JWM. Natural resistance against infections: focus on COVID-19. Trends Immunol. 2022;43:106\u201316. https:\/\/doi.org\/10.1016\/j.it.2021.12.001.","journal-title":"Trends Immunol"},{"key":"3042_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/imm.12223","volume":"141","author":"AJ Verrall","year":"2014","unstructured":"Verrall AJ, Netea MG, Alisjahbana B, Hill PC, van Crevel R. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology. 2014;141:506\u201313. https:\/\/doi.org\/10.1111\/imm.12223.","journal-title":"Immunology"},{"key":"3042_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.gendis.2015.02.008","volume":"2","author":"IC Withrock","year":"2015","unstructured":"Withrock IC, Anderson SJ, Jefferson MA, McCormack GR, Mlynarczyk GSA, Nakama A, et al. Genetic diseases conferring resistance to infectious diseases. Genes Dis. 2015;2:247\u201354. https:\/\/doi.org\/10.1016\/j.gendis.2015.02.008.","journal-title":"Genes Dis"},{"key":"3042_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/v14061243","author":"M Luo","year":"2022","unstructured":"Luo M. Natural immunity against HIV-1: progression of understanding after association studies. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14061243.","journal-title":"Viruses"},{"key":"3042_CR13","doi-asserted-by":"publisher","unstructured":"Lacap PA, Huntington JD, Luo M, Nagelkerke NJD, Bielawny T, Kimani J et al. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS. 2008;22. https:\/\/doi.org\/10.1097\/QAD.0b013e3282ffb3db.","DOI":"10.1097\/QAD.0b013e3282ffb3db"},{"key":"3042_CR14","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.1086\/655973","volume":"202","author":"G Pancino","year":"2010","unstructured":"Pancino G, Saez-Cirion A, Scott-Algara D, Paul P. Natural resistance to HIV infection: lessons learned from HIV-exposed uninfected individuals. J Infect Dis. 2010;202:S345-50. https:\/\/doi.org\/10.1086\/655973.","journal-title":"J Infect Dis"},{"key":"3042_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11524-005-9003-8","volume":"83","author":"M Marmor","year":"2006","unstructured":"Marmor M, Hertzmark K, Thomas SM, Halkitis PN, Vogler M. Resistance to HIV infection. J Urban Health. 2006;83:5\u201317. https:\/\/doi.org\/10.1007\/s11524-005-9003-8.","journal-title":"J Urban Health"},{"key":"3042_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/1744666X.2020.1732820","volume":"16","author":"C Fenizia","year":"2020","unstructured":"Fenizia C, Saulle I, Clerici M, Biasin M. Genetic and epigenetic regulation of natural resistance to HIV-1 infection: new approaches to unveil the HESN secret. Expert Rev Clin Immunol. 2020;16:429\u201345. https:\/\/doi.org\/10.1080\/1744666X.2020.1732820.","journal-title":"Expert Rev Clin Immunol"},{"key":"3042_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6096134","volume":"2017","author":"W Xu","year":"2017","unstructured":"Xu W, Li H, Wang Q, Hua C, Zhang H, Li W, et al. Advancements in developing strategies for sterilizing and functional HIV cures. BioMed Res Int. 2017;2017:6096134. https:\/\/doi.org\/10.1155\/2017\/6096134.","journal-title":"BioMed Res Int"},{"key":"3042_CR18","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1182\/blood-2011-10-381996","volume":"119","author":"D Mendoza","year":"2012","unstructured":"Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood. 2012;119:4645\u201355. https:\/\/doi.org\/10.1182\/blood-2011-10-381996.","journal-title":"Blood"},{"key":"3042_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-58696-y","volume":"10","author":"C Casado","year":"2020","unstructured":"Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V, et al. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Sci Rep. 2020;10:1\u201311. https:\/\/doi.org\/10.1038\/s41598-020-58696-y.","journal-title":"Sci Rep"},{"key":"3042_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2652-14-4","volume":"14","author":"SR Lewin","year":"2011","unstructured":"Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc. 2011;14:1\u20138. https:\/\/doi.org\/10.1186\/1758-2652-14-4.","journal-title":"J Int AIDS Soc"},{"key":"3042_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2016.02.001","volume":"18","author":"AR Cillo","year":"2016","unstructured":"Cillo AR, Mellors JW. Which therapeutic strategy will achieve a cure for HIV-1? Curr Opin Virol. 2016;18:14\u20139. https:\/\/doi.org\/10.1016\/j.coviro.2016.02.001.","journal-title":"Curr Opin Virol"},{"key":"3042_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","volume":"576","author":"T Ndung\u2019u","year":"2019","unstructured":"Ndung\u2019u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. Nature. 2019;576:397\u2013405. https:\/\/doi.org\/10.1038\/s41586-019-1841-8.","journal-title":"Nature"},{"key":"3042_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter G, Nowak D, Mossner M, Ganepola S, M\u00fcssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0802905.","journal-title":"N Engl J Med"},{"key":"3042_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00046","author":"V Kalidasan","year":"2020","unstructured":"Kalidasan V, Theva Das K. Lessons learned from failures and success stories of HIV breakthroughs: are we getting closer to an HIV cure? Front Microbiol. 2020. https:\/\/doi.org\/10.3389\/fmicb.2020.00046.","journal-title":"Front Microbiol"},{"key":"3042_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/BTT.S368152","volume":"16","author":"UR Kandula","year":"2022","unstructured":"Kandula UR, Wake AD. Promising stem cell therapy in the management of HIV and AIDS: a narrative review. Biol Targets Ther. 2022;16:89\u2013105. https:\/\/doi.org\/10.2147\/BTT.S368152.","journal-title":"Biol Targets Ther"},{"key":"3042_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100238","volume":"3","author":"G Marley","year":"2022","unstructured":"Marley G, Tan RKJ, Tang W. Stem cell research finds possible HIV cure with cord blood transplant. The Innovation. 2022;3:100238. https:\/\/doi.org\/10.1016\/j.xinn.2022.100238.","journal-title":"The Innovation"},{"key":"3042_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature. 2019;568:244\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1027-4.","journal-title":"Nature"},{"key":"3042_CR28","unstructured":"Dickter J, Weibel S, Cardoso A, Li S, Gendzekhadze K, Feng Y et al. The \u2018City of Hope\u2019 Patient: prolonged HIV-1 remission without antiretrovirals (ART) after allogeneic hematopoietic stem cell transplantation (aHCT) of CCR5\u220632\/\u220632 donor cells for acute myelogenous leukemia (AML). AIDS. 2022. Montreal; 2022. https:\/\/programme.aids2022.org\/Abstract\/Abstract\/?abstractid=12508."},{"key":"3042_CR29","doi-asserted-by":"publisher","unstructured":"Jensen B-EO, Knops E, Cords L, L\u00fcbke N, Salgado M, Busman-Sahay K et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5\u220632\/\u220632 allogeneic hematopoietic stem cell transplantation. Nat Med [Internet]. 2023;29:583\u20137. Available from: https:\/\/doi.org\/10.1038\/s41591-023-02213-x.","DOI":"10.1038\/s41591-023-02213-x"},{"key":"3042_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","volume":"186","author":"J Hsu","year":"2023","unstructured":"Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023;186:1115-1126.e8. https:\/\/doi.org\/10.1016\/j.cell.2023.02.030.","journal-title":"Cell"},{"key":"3042_CR31","unstructured":"S\u00e1ez-Ciri\u00f3n A, Mamez A-C, Avettand-Fenoel V, Thoueille P, Nabergoj M, Hentzien M et al. Absence of viral rebound for 18 months without antiretrovirals after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells to treat a biphenotypic sarcoma. IAS Conf HIV Sci. 2023. https:\/\/programme.ias2023.org\/Abstract\/Abstract\/?abstractid=5819."},{"key":"3042_CR32","unstructured":"Gaeble C, Kor S, Allers K, Mwangi D, Perotti M, Hanke K, et al. The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT\/\u220632 allogeneic hematopoietic stem cell transplantation. AIDS 2024 25th Int AIDS Conf. 2024. https:\/\/programme.aids2024.org\/Abstract\/Abstract\/?abstractid=12163."},{"key":"3042_CR33","unstructured":"American Foundation for AIDS Research. The. French Patient May Be the Latest Person Cured of HIV A woman who received a stem cell transplant with HIV- resistant donor cells appears to be free of the virus [Internet]. 2025. Available from: https:\/\/www.amfar.org\/news\/the-french-patient-may-be-the-latest-person-cured-of-hiv\/."},{"key":"3042_CR34","unstructured":"Rubinstein P, Liliana P, Damiano R, Hannah S, Karen S, Kadkol S et al. Sustained HIV Remission Despite Transient Rebound Viremia After a CCR5\u2206\/\u220632 Stem Cell Transplant. Conf Retroviruses Opportunistic Infect [Internet]. San Francisco, CA; 2025. Available from: https:\/\/www.natap.org\/2025\/CROI\/croi_75.htm."},{"key":"3042_CR35","unstructured":"Marius T, Myhre AE, Gullaksen HH, S\u00f8gaard O, Tolstrup M, Salgado M et al. HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant From CCR5\u220632\/\u220632 Sibling Donor. Conf Retroviruses Opportunistic Infect [Internet]. San Francisco, CA; 2025. Available from: https:\/\/www.croiconference.org\/abstract\/3818-2025\/."},{"key":"3042_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13557","author":"S Payra","year":"2023","unstructured":"Payra S, Manjhi PK, Singh S, Kumar R, Singh SK, Kumar A, et al. HIV cure: are we going to make history? HIV Med. 2023. https:\/\/doi.org\/10.1111\/hiv.13557.","journal-title":"HIV Med"},{"key":"3042_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.humimm.2017.10.001","volume":"78","author":"UV Solloch","year":"2017","unstructured":"Solloch UV, Lang K, Lange V, B\u00f6hme I, Schmidt AH, Sauter J. Frequencies of gene variant CCR5-\u220632 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 National DKMS donor centers. Hum Immunol. 2017;78:710\u20137. https:\/\/doi.org\/10.1016\/j.humimm.2017.10.001.","journal-title":"Hum Immunol"},{"key":"3042_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030339","volume":"3","author":"J Novembre","year":"2005","unstructured":"Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 \u039432 HIV-resistance allele. PLoS Biol. 2005;3:e339. https:\/\/doi.org\/10.1371\/journal.pbio.0030339.","journal-title":"PLoS Biol"},{"key":"3042_CR39","doi-asserted-by":"publisher","unstructured":"Arslan S, Litzow MR, Cummins NW, Rizza SA, Badley AD, Navarro W et al. Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biol Blood Marrow Transplant [Internet]. 2019;25:e260\u20137. Available from: https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.021.","DOI":"10.1016\/j.bbmt.2019.03.021"},{"key":"3042_CR40","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","volume":"7","author":"SM Kimani","year":"2020","unstructured":"Kimani SM, Painschab MS, Horner M-J, Muchengeti M, Fedoriw Y, Shiels MS, et al. Epidemiology of haematological malignancies in people living with HIV. Lancet HIV. 2020;7:e641\u201351.","journal-title":"Lancet HIV"},{"key":"3042_CR41","doi-asserted-by":"publisher","unstructured":"Buck AM, LaFranchi BH, Henrich TJ. Gaining momentum: stem cell therapies for HIV cure. Curr Opin HIV AIDS. 2024;19. https:\/\/doi.org\/10.1097\/COH.0000000000000859.","DOI":"10.1097\/COH.0000000000000859"},{"key":"3042_CR42","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1021\/acsabm.4c01544","volume":"8","author":"M Zhao","year":"2025","unstructured":"Zhao M, Wen J, Chen ISY, Liu J, Lu Y. Excision of HIV-1 provirus in human primary cells with nanocapsuled TALEN proteins. ACS Appl Bio Mater. 2025;8:1227\u201339. https:\/\/doi.org\/10.1021\/acsabm.4c01544.","journal-title":"ACS Appl Bio Mater"},{"key":"3042_CR43","doi-asserted-by":"publisher","unstructured":"Yin C, Zhang T, Qu X, Zhang Y, Putatunda R, Xiao X et al. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther. 2017;25:1168\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.012.","DOI":"10.1016\/j.ymthe.2017.03.012"},{"key":"3042_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61626-x","volume":"14","author":"W Khamaikawin","year":"2024","unstructured":"Khamaikawin W, Saisawang C, Tassaneetrithep B, Bhukhai K, Phanthong P, Borwornpinyo S, et al. CRISPR\/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1. Sci Rep. 2024;14:10852. https:\/\/doi.org\/10.1038\/s41598-024-61626-x.","journal-title":"Sci Rep"},{"key":"3042_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4939-2432-5_6","volume":"848","author":"TI Cornu","year":"2015","unstructured":"Cornu TI, Mussolino C, Bloom K, Cathomen T. Editing CCR5: a novel approach to HIV gene therapy. Adv Exp Med Biol. 2015;848:117\u201330. https:\/\/doi.org\/10.1007\/978-1-4939-2432-5_6.","journal-title":"Adv Exp Med Biol"},{"key":"3042_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/COH.0000000000000858","volume":"19","author":"H Su","year":"2024","unstructured":"Su H, Mueller A, Goldstein H. Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission. Curr Opin HIV AIDS. 2024;19:169\u201378. https:\/\/doi.org\/10.1097\/COH.0000000000000858.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR47","doi-asserted-by":"publisher","unstructured":"Choudhary MC, Cyktor JC, Riddler SA. Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir. J Virus Erad. 2022;8:100073. https:\/\/doi.org\/10.1016\/j.jve.2022.100073.","DOI":"10.1016\/j.jve.2022.100073"},{"key":"3042_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/fvl-2018-0207","volume":"14","author":"C Lopez-Galindez","year":"2019","unstructured":"Lopez-Galindez C. HIV long-term non-progressors elite controllers: an interplay between host, immune and viral factors. Future Virol. 2019;14:287\u201397. https:\/\/doi.org\/10.2217\/fvl-2018-0207.","journal-title":"Future Virol"},{"key":"3042_CR49","doi-asserted-by":"publisher","unstructured":"Marta C-L, Athina K, Mar\u00eda P, Ruth P, Dan O, Esther J-M et al. Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors. J Virol [Internet]. 2022;96:e01499-21. Available from: https:\/\/doi.org\/10.1128\/JVI.01499-21.","DOI":"10.1128\/JVI.01499-21"},{"key":"3042_CR50","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1017\/S0950268820000540","volume":"148","author":"XC Jia","year":"2020","unstructured":"Jia XC, Xia ZH, Shi N, Wang YP, Luo ZX, Yang YL, et al. The factors associated with natural disease progression from HIV to AIDS in the absence of ART, a propensity score matching analysis. Epidemiol Infect. 2020;148:e57. https:\/\/doi.org\/10.1017\/S0950268820000540.","journal-title":"Epidemiol Infect"},{"key":"3042_CR51","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","volume":"27","author":"SG Deeks","year":"2007","unstructured":"Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.010.","journal-title":"Immunity"},{"key":"3042_CR52","doi-asserted-by":"publisher","unstructured":"Lambotte O. Long-Term Nonprogressors and Elite Controllers BT - Encyclopedia of AIDS. In: Hope TJ, Stevenson M, Richman D, editors. New York, NY: Springer New York; 2014. pp. 1\u201312. Available from: https:\/\/doi.org\/10.1007\/978-1-4614-9610-6_191-1.","DOI":"10.1007\/978-1-4614-9610-6_191-1"},{"key":"3042_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/QAI.0b013e3181945f1e","volume":"50","author":"MM Sajadi","year":"2009","unstructured":"Sajadi MM, Constantine NT, Mann DL, Charurat M, Dadzan E, Kadlecik P, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr. 2009;50:403\u20138. https:\/\/doi.org\/10.1097\/QAI.0b013e3181945f1e.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3042_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/COH.0b013e328344f35e","volume":"6","author":"JF Okulicz","year":"2011","unstructured":"Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS. 2011;6:163\u20138. https:\/\/doi.org\/10.1097\/COH.0b013e328344f35e.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR55","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.medj.2024.06.008","volume":"5","author":"M Salgado","year":"2024","unstructured":"Salgado M, Migueles SA, Yu XG, Martinez-Picado J. Exceptional, naturally occurring HIV-1 control: insight into a functional cure. Med. 2024;5:1071\u201382. https:\/\/doi.org\/10.1016\/j.medj.2024.06.008.","journal-title":"Med"},{"key":"3042_CR56","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1097\/01.aids.0000194134.28135.cd","volume":"19","author":"Y Madec","year":"2005","unstructured":"Madec Y, Boufassa F, Porter K, Meyer L. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS. 2005;19:2001\u20137. https:\/\/doi.org\/10.1097\/01.aids.0000194134.28135.cd.","journal-title":"AIDS"},{"key":"3042_CR57","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/infdis\/jiu809","volume":"211","author":"TA Crowell","year":"2015","unstructured":"Crowell TA, Gebo KA, Blankson JN, Korthuis PT, Yehia BR, Rutstein RM, et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015;211:1692\u2013702. https:\/\/doi.org\/10.1093\/infdis\/jiu809.","journal-title":"J Infect Dis"},{"key":"3042_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/QAD.0000000000002043","volume":"33","author":"VA Vieira","year":"2019","unstructured":"Vieira VA, Zuidewind P, Muenchhoff M, Roider J, Millar J, Clapson M, et al. Strong sex bias in elite control of paediatric HIV infection. AIDS. 2019;33:67\u201375. https:\/\/doi.org\/10.1097\/QAD.0000000000002043.","journal-title":"AIDS"},{"key":"3042_CR59","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/QAD.0000000000001443","volume":"31","author":"OO Yang","year":"2017","unstructured":"Yang OO, Cumberland WG, Escobar R, Liao D, Chew KW. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. AIDS. 2017;31:1091\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000001443.","journal-title":"AIDS"},{"key":"3042_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0354-5","volume":"14","author":"SSD de Azevedo","year":"2017","unstructured":"de Azevedo SSD, Caetano DG, C\u00f4rtes FH, Teixeira SLM, dos Santos Silva K, Hoagland B, et al. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers. Retrovirology. 2017;14:29. https:\/\/doi.org\/10.1186\/s12977-017-0354-5.","journal-title":"Retrovirology"},{"key":"3042_CR61","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/cid\/cir484","volume":"53","author":"TD Ruel","year":"2011","unstructured":"Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kamya M, et al. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis. 2011;53:592\u20139. https:\/\/doi.org\/10.1093\/cid\/cir484.","journal-title":"Clin Infect Dis"},{"key":"3042_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002030-200201040-00012","volume":"16","author":"European Collaborative Study","year":"2002","unstructured":"European Collaborative Study. Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys? AIDS. 2002;16:97\u2013104. https:\/\/doi.org\/10.1097\/00002030-200201040-00012.","journal-title":"AIDS"},{"key":"3042_CR63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/01.aids.0000161765.75663.27","volume":"19","author":"M Prins","year":"2005","unstructured":"Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS. 2005;19:357\u201370. https:\/\/doi.org\/10.1097\/01.aids.0000161765.75663.27.","journal-title":"AIDS"},{"issue":"Suppl 3","key":"3042_CR64","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1093\/infdis\/jiu175","volume":"209","author":"MM Addo","year":"2014","unstructured":"Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis. 2014;209(Suppl 3):S86\u201392. https:\/\/doi.org\/10.1093\/infdis\/jiu175.","journal-title":"J Infect Dis"},{"key":"3042_CR65","doi-asserted-by":"publisher","unstructured":"Portales P, Clot J, Corbeau P. Sex Differences in HIV-1 Viral Load Due to Sex Difference in CCR5 Expression. Ann Intern Med. 2001;134:81\u20132. https:\/\/doi.org\/10.7326\/0003-4819-134-1-200101020-00023.","DOI":"10.7326\/0003-4819-134-1-200101020-00023"},{"key":"3042_CR66","unstructured":"Weerasuria M, Ellis H. Why we need more women in HIV cure trials [Internet]. Natl. Assoc. People with HIV Aust. 2023. Available from: https:\/\/shecancode.io\/blog\/why-we-need-more-women-in-stem\/."},{"key":"3042_CR67","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11904-018-0383-2","volume":"15","author":"EP Scully","year":"2018","unstructured":"Scully EP. Sex differences in HIV infection. Curr HIV AIDS Rep. 2018;15:136\u201346. https:\/\/doi.org\/10.1007\/s11904-018-0383-2.","journal-title":"Curr HIV AIDS Rep"},{"key":"3042_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13072-024-00564-4","volume":"18","author":"P Letchumanan","year":"2025","unstructured":"Letchumanan P, Theva Das K. The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review. Epigenetics Chromatin. 2025;18:1. https:\/\/doi.org\/10.1186\/s13072-024-00564-4.","journal-title":"Epigenetics Chromatin"},{"key":"3042_CR69","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2815","volume":"10","author":"C Libert","year":"2010","unstructured":"Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10:594\u2013604. https:\/\/doi.org\/10.1038\/nri2815.","journal-title":"Nat Rev Immunol"},{"key":"3042_CR70","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3390\/microorganisms8111787","volume":"8","author":"EP Browne","year":"2020","unstructured":"Browne EP. The role of toll-like receptors in retroviral infection. Microorganisms. 2020;8:1787. https:\/\/doi.org\/10.3390\/microorganisms8111787.","journal-title":"Microorganisms"},{"key":"3042_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.601170","volume":"11","author":"A Fathi","year":"2020","unstructured":"Fathi A, Addo MM, Dahlke C. Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens. Front Immunol. 2020;11:601170. https:\/\/doi.org\/10.3389\/fimmu.2020.601170.","journal-title":"Front Immunol"},{"key":"3042_CR72","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/nm.2004","volume":"15","author":"A Meier","year":"2009","unstructured":"Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15:955\u20139. https:\/\/doi.org\/10.1038\/nm.2004.","journal-title":"Nat Med"},{"key":"3042_CR73","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.4049\/jimmunol.1501684","volume":"195","author":"M Griesbeck","year":"2015","unstructured":"Griesbeck M, Ziegler S, Laffont S, Smith N, Chauveau L, Tomezsko P, et al. Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-\u03b1 production in women. J Immunol. 2015;195:5327\u201336. https:\/\/doi.org\/10.4049\/jimmunol.1501684.","journal-title":"J Immunol"},{"key":"3042_CR74","doi-asserted-by":"publisher","unstructured":"Moran JA, Turner SR, Marsden MD. Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.905773.","DOI":"10.3389\/fimmu.2022.905773"},{"key":"3042_CR75","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1086\/315776","volume":"182","author":"SM Smith","year":"2000","unstructured":"Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of Simian immunodeficiency virus. J Infect Dis. 2000;182:708\u201315. https:\/\/doi.org\/10.1086\/315776.","journal-title":"J Infect Dis"},{"key":"3042_CR76","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.virol.2013.05.027","volume":"443","author":"EL Szotek","year":"2013","unstructured":"Szotek EL, Narasipura SD, Al-Harthi L. 17\u03b2-estradiol inhibits HIV-1 by inducing a complex formation between \u03b2-catenin and Estrogen receptor \u03b1 on the HIV promoter to suppress HIV transcription. Virology. 2013;443:375\u201383. https:\/\/doi.org\/10.1016\/j.virol.2013.05.027.","journal-title":"Virology"},{"key":"3042_CR77","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1089\/aid.2007.0108","volume":"24","author":"SN Asin","year":"2008","unstructured":"Asin SN, Heimberg AM, Eszterhas SK, Rollenhagen C, Howell AL. Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses. 2008;24:701\u201316. https:\/\/doi.org\/10.1089\/aid.2007.0108.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3042_CR78","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1126\/science.1195271","volume":"330","author":"F Pereyra","year":"2010","unstructured":"Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330:1551\u20137. https:\/\/doi.org\/10.1126\/science.1195271.","journal-title":"Science"},{"key":"3042_CR79","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1086\/433188","volume":"41","author":"O Lambotte","year":"2005","unstructured":"Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053\u20136. https:\/\/doi.org\/10.1086\/433188.","journal-title":"Clin Infect Dis"},{"key":"3042_CR80","doi-asserted-by":"publisher","first-page":"100963","DOI":"10.1016\/j.eclinm.2021.100963","volume":"37","author":"L Pla\u00e7ais","year":"2021","unstructured":"Pla\u00e7ais L, Boufassa F, L\u00e9curoux C, Gardiennet E, Avettand-Fenoel V, Saez-Cirion A, et al. Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine. 2021;37:100963. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100963.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"3042_CR81","doi-asserted-by":"publisher","first-page":"e02338","DOI":"10.1128\/mBio.02338-17","volume":"9","author":"C Casado","year":"2018","unstructured":"Casado C, Marrero-Hern\u00e1ndez S, M\u00e1rquez-Arce D, Pernas M, Marfil S, Borr\u00e0s-Gra\u00f1ana F, et al. Viral characteristics associated with the clinical nonprogressor phenotype are inherited by viruses from a cluster of HIV-1 elite controllers. MBio. 2018;9(2)e02338\u201317. https:\/\/doi.org\/10.1128\/mBio.02338-17.","journal-title":"MBio"},{"key":"3042_CR82","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1182\/blood-2011-10-381996","volume":"119","author":"D Mendoza","year":"2012","unstructured":"Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood. 2012;119:4645\u201355. https:\/\/doi.org\/10.1182\/blood-2011-10-381996.","journal-title":"Blood"},{"key":"3042_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-2961-8","volume":"18","author":"Y Moosa","year":"2018","unstructured":"Moosa Y, Tanko RF, Ramsuran V, Singh R, Madzivhandila M, Yende-Zuma N, et al. Case report: mechanisms of HIV elite control in two African women. BMC Infect Dis. 2018;18:1\u20137. https:\/\/doi.org\/10.1186\/s12879-018-2961-8.","journal-title":"BMC Infect Dis"},{"key":"3042_CR84","doi-asserted-by":"crossref","unstructured":"Zaunders J, Dyer WB, Churchill M, Munier CML, Cunningham PH, Suzuki K et al. Possible clearance of transfusion-acquired nef\/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 \u220632 heterozygous and HLA-B57 genotype. J. Virus Erad. England; 2019. pp. 73\u201383.","DOI":"10.1016\/S2055-6640(20)30056-X"},{"key":"3042_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","volume":"585","author":"C Jiang","year":"2020","unstructured":"Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020;585:261\u20137. https:\/\/doi.org\/10.1038\/s41586-020-2651-8.","journal-title":"Nature"},{"key":"3042_CR86","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4103\/0970-258X.316250","volume":"33","author":"S Shanmukhappa","year":"2020","unstructured":"Shanmukhappa S, Abraham R, Anand A, Pillala P. A 38-year-old HIV elite controller from Bengaluru, Karnataka, India. Natl Med J India. 2020;33:210\u20132. https:\/\/doi.org\/10.4103\/0970-258X.316250.","journal-title":"Natl Med J India"},{"key":"3042_CR87","doi-asserted-by":"publisher","first-page":"214","DOI":"10.46527\/2582-5038.214","volume":"5","author":"M Sankaranantham","year":"2022","unstructured":"Sankaranantham M. Viremic controller -A case report. Clin Case Rep Open Access. 2022;5:214. https:\/\/doi.org\/10.46527\/2582-5038.214.","journal-title":"Clin Case Rep Open Access"},{"issue":"11","key":"3042_CR88","doi-asserted-by":"publisher","first-page":"e149414","DOI":"10.1172\/JCI149414","volume":"131","author":"JZ Li","year":"2021","unstructured":"Li JZ, Blankson JN. How elite controllers and posttreatment controllers inform our search for an HIV-1 cure. J Clin Invest. 2021;131(11):e149414. https:\/\/doi.org\/10.1172\/JCI149414.","journal-title":"J Clin Invest"},{"key":"3042_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.858383","volume":"13","author":"S Sugawara","year":"2022","unstructured":"Sugawara S, Reeves RK, Jost S. Learning to be elite: lessons from HIV-1 controllers and animal models on trained innate immunity and virus suppression. Front Immunol. 2022;13:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2022.858383.","journal-title":"Front Immunol"},{"key":"3042_CR90","doi-asserted-by":"publisher","unstructured":"Yuan X, Lai Y. Bibliometric and visualized analysis of elite controllers based on CiteSpace: landscapes, hotspots, and frontiers. Front Cell Infect Microbiol. 2023;13. https:\/\/doi.org\/10.3389\/fcimb.2023.1147265.","DOI":"10.3389\/fcimb.2023.1147265"},{"key":"3042_CR91","unstructured":"Highleyman L. First woman May be cured of HIV without a bone marrow transplant. POZ. 2020. https:\/\/www.poz.com\/article\/first-woman-may-cured-hiv-without-bone-marrow-transplant."},{"key":"3042_CR92","unstructured":"Cairns G. Loreen Willenberg\u2019s HIV seems to have disappeared. Is this good news for the rest of us ? NAM-AIDSmap. 2020. https:\/\/www.aidsmap.com\/news\/sep-2020\/loreen-willenbergs-hiv-seems-have-disappeared-good-news-rest-us."},{"key":"3042_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4097","volume":"13","author":"X Lian","year":"2021","unstructured":"Lian X, Gao C, Sun X, Jiang C, Einkauf KB, Seiger KW, et al. Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Sci Transl Med. 2021;13:eabl4097. https:\/\/doi.org\/10.1126\/scitranslmed.abl4097.","journal-title":"Sci Transl Med"},{"key":"3042_CR94","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7326\/L21-0297","volume":"175","author":"G Turk","year":"2022","unstructured":"Turk G, Seiger K, Lian X, Sun W, Parsons EM, Gao C, et al. A possible sterilizing cure of HIV-1 infection without stem cell transplantation. Ann Intern Med. 2022;175:95\u2013100. https:\/\/doi.org\/10.7326\/L21-0297.","journal-title":"Ann Intern Med"},{"key":"3042_CR95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218960120","volume":"120","author":"B Etemad","year":"2023","unstructured":"Etemad B, Sun X, Li Y, Melberg M, Moisi D, Gottlieb R, et al. HIV post-treatment controllers have distinct immunological and virological features. Proc Natl Acad Sci U S A. 2023;120:e2218960120. https:\/\/doi.org\/10.1073\/pnas.2218960120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3042_CR96","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1073\/pnas.1419162112","volume":"112","author":"JM Conway","year":"2015","unstructured":"Conway JM, Perelson AS. Post-treatment control of HIV infection. Proc Natl Acad Sci U S A. 2015;112:5467\u201372. https:\/\/doi.org\/10.1073\/pnas.1419162112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3042_CR97","doi-asserted-by":"publisher","unstructured":"Zhou C, Wu Y, Zhang Y, Wang Y, Wu H, Zhang T et al. Factors associated with post-treatment control of viral load in HIV-infected patients: a systematic review and meta-analysis. Int J Infect Dis. 2023;129:216\u201327. https:\/\/doi.org\/10.1016\/j.ijid.2023.01.025.","DOI":"10.1016\/j.ijid.2023.01.025"},{"key":"3042_CR98","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.it.2007.09.002","volume":"28","author":"A S\u00e1ez-Ciri\u00f3n","year":"2007","unstructured":"S\u00e1ez-Ciri\u00f3n A, Pancino G, Sinet M, Venet A, Lambotte O. HIV controllers: how do they tame the virus? Trends Immunol. 2007;28:532\u201340. https:\/\/doi.org\/10.1016\/j.it.2007.09.002.","journal-title":"Trends Immunol"},{"key":"3042_CR99","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/COH.0b013e328345a328","volume":"6","author":"B Autran","year":"2011","unstructured":"Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6:181\u20137. https:\/\/doi.org\/10.1097\/COH.0b013e328345a328.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR100","first-page":"282","volume":"30","author":"CT Tiemessen","year":"2012","unstructured":"Tiemessen CT, Martinson N. Elite controllers: understanding natural suppressive control of HIV-1 infection. Contin Med Educ. 2012;30:282\u20135.","journal-title":"Contin Med Educ"},{"key":"3042_CR101","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tim.2014.11.003","volume":"23","author":"LR Cockerham","year":"2015","unstructured":"Cockerham LR, Hatano H. Elite control of HIV: is this the right model for a functional cure? Trends Microbiol. 2015;23:71\u20135. https:\/\/doi.org\/10.1016\/j.tim.2014.11.003.","journal-title":"Trends Microbiol"},{"key":"3042_CR102","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tips.2009.09.005","volume":"30","author":"KA O\u2019Connell","year":"2009","unstructured":"O\u2019Connell KA, Bailey JR, Blankson JN. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci. 2009;30:631\u20137. https:\/\/doi.org\/10.1016\/j.tips.2009.09.005.","journal-title":"Trends Pharmacol Sci"},{"key":"3042_CR103","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2217\/fmb-2017-0163","volume":"12","author":"ME May","year":"2017","unstructured":"May ME, Kwaa AK, Blankson JN. HIV-1 reservoirs in elite controllers: clues for developing a functional cure? Future Microbiol. 2017;12:1019\u201322. https:\/\/doi.org\/10.2217\/fmb-2017-0163.","journal-title":"Future Microbiol"},{"key":"3042_CR104","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.1128\/JVI.00535-08","volume":"82","author":"T Miura","year":"2008","unstructured":"Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol. 2008;82:8422\u201330. https:\/\/doi.org\/10.1128\/JVI.00535-08.","journal-title":"J Virol"},{"key":"3042_CR105","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1128\/JVI.02165-06","volume":"81","author":"JN Blankson","year":"2007","unstructured":"Blankson JN, Bailey JR, Thayil S, Yang H-C, Lassen K, Lai J, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol. 2007;81:2508\u201318. https:\/\/doi.org\/10.1128\/JVI.02165-06.","journal-title":"J Virol"},{"key":"3042_CR106","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1086\/605446","volume":"200","author":"F Pereyra","year":"2009","unstructured":"Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200:984\u201390. https:\/\/doi.org\/10.1086\/605446.","journal-title":"J Infect Dis"},{"key":"3042_CR107","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1128\/JVI.01763-08","volume":"83","author":"H Hatano","year":"2009","unstructured":"Hatano H, Delwart EL, Norris PJ, Lee T-H, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009;83:329\u201335. https:\/\/doi.org\/10.1128\/JVI.01763-08.","journal-title":"J Virol"},{"key":"3042_CR108","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/COH.0000000000000693","volume":"16","author":"CA Hartana","year":"2021","unstructured":"Hartana CA, Yu XG. Immunological effector mechanisms in HIV-1 elite controllers. Curr Opin HIV AIDS. 2021;16:243\u20138. https:\/\/doi.org\/10.1097\/COH.0000000000000693.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR109","first-page":"245","volume":"90","author":"E Gonzalo-Gil","year":"2017","unstructured":"Gonzalo-Gil E, Ikediobi U, Sutton RE. Mechanisms of virologic control and clinical characteristics of HIV\u2009+\u2009elite\/viremic controllers. Yale J Biol Med. 2017;90:245\u201359.","journal-title":"Yale J Biol Med"},{"key":"3042_CR110","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1086\/524143","volume":"197","author":"PW Hunt","year":"2008","unstructured":"Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4\u2009+\u2009T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126\u201333. https:\/\/doi.org\/10.1086\/524143.","journal-title":"J Infect Dis"},{"key":"3042_CR111","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1086\/646609","volume":"200","author":"JF Okulicz","year":"2009","unstructured":"Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US department of defense HIV natural history study. J Infect Dis. 2009;200:1714\u201323. https:\/\/doi.org\/10.1086\/646609.","journal-title":"J Infect Dis"},{"key":"3042_CR112","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/QAD.0b013e3283519b22","volume":"26","author":"Y Yang","year":"2012","unstructured":"Yang Y, Al-Mozaini M, Buzon MJ, Beamon J, Ferrando-Martinez S, Ruiz-Mateos E, et al. CD4 T-cell regeneration in HIV-1 elite controllers. AIDS. 2012;26:701\u20136. https:\/\/doi.org\/10.1097\/QAD.0b013e3283519b22.","journal-title":"AIDS"},{"key":"3042_CR113","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nri3478","volume":"13","author":"BD Walker","year":"2013","unstructured":"Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013;13:487\u201398. https:\/\/doi.org\/10.1038\/nri3478.","journal-title":"Nat Rev Immunol"},{"key":"3042_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.780922","volume":"13","author":"Y Shi","year":"2022","unstructured":"Shi Y, Su J, Chen R, Wei W, Yuan Z, Chen X, et al. The role of innate immunity in natural elite controllers of HIV-1 infection. Front Immunol. 2022;13:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2022.780922.","journal-title":"Front Immunol"},{"key":"3042_CR115","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.antiviral.2009.08.007","volume":"85","author":"JN Blankson","year":"2010","unstructured":"Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010;85:295\u2013302. https:\/\/doi.org\/10.1016\/j.antiviral.2009.08.007.","journal-title":"Antiviral Res"},{"key":"3042_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2013.00086","volume":"4","author":"L Genovese","year":"2013","unstructured":"Genovese L, Nebuloni M, Alfano M. Cell-mediated immunity in elite controllers naturally controlling HIV viral load. Front Immunol. 2013;4:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2013.00086.","journal-title":"Front Immunol"},{"key":"3042_CR117","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","volume":"107","author":"MR Betts","year":"2006","unstructured":"Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8\u2009+\u2009T cells. Blood. 2006;107:4781\u20139. https:\/\/doi.org\/10.1182\/blood-2005-12-4818.","journal-title":"Blood"},{"key":"3042_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29646","volume":"96","author":"N Rall\u00f3n","year":"2024","unstructured":"Rall\u00f3n N, Jim\u00e9nez-Carretero D, Restrepo C, Ligos JM, Valent\u00edn-Quiroga J, Mahillo I, et al. A specific natural killer cells phenotypic signature associated to long term elite control of HIV infection. J Med Virol. 2024;96:e29646. https:\/\/doi.org\/10.1002\/jmv.29646.","journal-title":"J Med Virol"},{"issue":"20","key":"3042_CR119","doi-asserted-by":"publisher","first-page":"e182660","DOI":"10.1172\/jci.insight.182660","volume":"9","author":"N S\u00e1nchez-Gaona","year":"2024","unstructured":"S\u00e1nchez-Gaona N, Gallego-Cort\u00e9s A, Astorga-Gamaza A, Rall\u00f3n N, Benito JM, Ruiz-Mateos E, et al. NKG2C and NKG2A coexpression defines a highly functional antiviral NK population in spontaneous HIV control. JCI Insight. 2024;9(20):e182660. https:\/\/doi.org\/10.1172\/jci.insight.182660.","journal-title":"JCI Insight"},{"key":"3042_CR120","doi-asserted-by":"publisher","unstructured":"Zhang Z, Zhou Y, Lu J, Chen Y-F, Hu H-Y, Xu X-Q et al. Changes in NK Cell Subsets and Receptor Expressions in HIV-1 Infected Chronic Patients and HIV Controllers. Front Immunol. 2021;792775. https:\/\/doi.org\/10.3389\/fimmu.2021.792775.","DOI":"10.3389\/fimmu.2021.792775"},{"key":"3042_CR121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QAI.0b013e3182100c1b","volume":"57","author":"MM Sajadi","year":"2011","unstructured":"Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis GK, et al. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr. 2011;57:9\u201315. https:\/\/doi.org\/10.1097\/QAI.0b013e3182100c1b.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3042_CR122","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/QAD.0b013e328329f97d","volume":"23","author":"O Lambotte","year":"2009","unstructured":"Lambotte O, Ferrari G, Moog C, Yates NL, Liao H-X, Parks RJ, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23:897\u2013906. https:\/\/doi.org\/10.1097\/QAD.0b013e328329f97d.","journal-title":"AIDS"},{"issue":"3","key":"3042_CR123","doi-asserted-by":"publisher","first-page":"e00317","DOI":"10.1128\/mBio.00317-18","volume":"9","author":"M Claireaux","year":"2018","unstructured":"Claireaux M, Galperin M, Benati D, Nou\u00ebl A, Mukhopadhyay M, Klingler J, et al. A high frequency of HIV-specific circulating follicular helper T cells is associated with preserved memory B cell responses in HIV controllers. MBio. 2018;9(3):e00317\u20138. https:\/\/doi.org\/10.1128\/mBio.00317-18.","journal-title":"MBio"},{"key":"3042_CR124","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chom.2019.09.016","volume":"26","author":"D Pinto","year":"2019","unstructured":"Pinto D, Fenwick C, Caillat C, Silacci C, Guseva S, Dehez F, et al. Structural basis for broad HIV-1 neutralization by the MPER-specific human broadly neutralizing antibody LN01. Cell Host Microbe. 2019;26:623-637.e8. https:\/\/doi.org\/10.1016\/j.chom.2019.09.016.","journal-title":"Cell Host Microbe"},{"key":"3042_CR125","doi-asserted-by":"publisher","unstructured":"Th\u00f8rner L, Wegnerrup C, Holm L, H\u00f8rup M, Kronborg G, Pedersen C, Schade C et al. Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load. Infect Genet Evol. 2016;41:185\u201390. https:\/\/doi.org\/10.1016\/j.meegid.2016.03.037.","DOI":"10.1016\/j.meegid.2016.03.037"},{"key":"3042_CR126","doi-asserted-by":"publisher","first-page":"14658","DOI":"10.1073\/pnas.1514867112","volume":"112","author":"PJ McLaren","year":"2015","unstructured":"McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, et al. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proc Natl Acad Sci U S A. 2015;112:14658\u201363. https:\/\/doi.org\/10.1073\/pnas.1514867112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3042_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107214","volume":"26","author":"LM Real","year":"2023","unstructured":"Real LM, S\u00e1ez ME, Corma-G\u00f3mez A, Gonzalez-P\u00e9rez A, Thorball C, Ruiz R, et al. A metagenome-wide association study of HIV disease progression in HIV controllers. iScience. 2023;26:107214. https:\/\/doi.org\/10.1016\/j.isci.2023.107214.","journal-title":"iScience"},{"key":"3042_CR128","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1093\/infdis\/jiu342","volume":"210","author":"S Le Clerc","year":"2014","unstructured":"Le Clerc S, Delaneau O, Coulonges C, Spadoni J-L, Labib T, Laville V, et al. Evidence after imputation for a role of MICA variants in nonprogression and elite control of HIV type 1 infection. J Infect Dis. 2014;210:1946\u201350. https:\/\/doi.org\/10.1093\/infdis\/jiu342.","journal-title":"J Infect Dis"},{"key":"3042_CR129","doi-asserted-by":"publisher","first-page":"e1000791","DOI":"10.1371\/journal.pgen.1000791","volume":"5","author":"J Fellay","year":"2009","unstructured":"Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009;5:e1000791. https:\/\/doi.org\/10.1371\/journal.pgen.1000791.","journal-title":"PLoS Genet"},{"key":"3042_CR130","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1126\/science.1143767","volume":"317","author":"J Fellay","year":"2007","unstructured":"Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944\u20137. https:\/\/doi.org\/10.1126\/science.1143767.","journal-title":"Science"},{"key":"3042_CR131","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.immuni.2012.09.005","volume":"37","author":"PJR Goulder","year":"2012","unstructured":"Goulder PJR, Walker BD. HIV and HLA class I: an evolving relationship. Immunity. 2012;37:426\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2012.09.005.","journal-title":"Immunity"},{"key":"3042_CR132","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1399-0039.2009.01337.x","volume":"74","author":"G Kaur","year":"2009","unstructured":"Kaur G, Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue Antigens. 2009;74:373\u201385. https:\/\/doi.org\/10.1111\/j.1399-0039.2009.01337.x.","journal-title":"Tissue Antigens"},{"key":"3042_CR133","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2796.2008.02041.x","volume":"265","author":"L Piacentini","year":"2008","unstructured":"Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med. 2008;265:110\u201324. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.02041.x.","journal-title":"J Intern Med"},{"key":"3042_CR134","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-immunol-031210-101332","volume":"29","author":"AA Bashirova","year":"2011","unstructured":"Bashirova AA, Thomas R, Carrington M. HLA\/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol. 2011;29:295\u2013317. https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101332.","journal-title":"Annu Rev Immunol"},{"key":"3042_CR135","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/1471-2334-13-405","volume":"13","author":"Y Jiang","year":"2013","unstructured":"Jiang Y, Chen O, Cui C, Zhao B, Han X, Zhang Z, et al. KIR3DS1\/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. BMC Infect Dis. 2013;13:405. https:\/\/doi.org\/10.1186\/1471-2334-13-405.","journal-title":"BMC Infect Dis"},{"key":"3042_CR136","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins DR, Gaiha GD, Walker BD. CD8\u2009+\u2009T cells in HIV control, cure and prevention. Nat Rev Immunol. 2020;20:471\u201382. https:\/\/doi.org\/10.1038\/s41577-020-0274-9.","journal-title":"Nat Rev Immunol"},{"key":"3042_CR137","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/QAD.0000000000000572","volume":"29","author":"M Abdel-Mohsen","year":"2015","unstructured":"Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, et al. Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS. 2015;29:411\u201320. https:\/\/doi.org\/10.1097\/QAD.0000000000000572.","journal-title":"AIDS"},{"key":"3042_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4690-10-106","volume":"10","author":"M Abdel-Mohsen","year":"2013","unstructured":"Abdel-Mohsen M, Raposo RAS, Deng X, Li M, Liegler T, Sinclair E, et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology. 2013;10:1\u201313. https:\/\/doi.org\/10.1186\/1742-4690-10-106.","journal-title":"Retrovirology"},{"key":"3042_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2023.199162","volume":"334","author":"K Jitobaom","year":"2023","unstructured":"Jitobaom K, Sirihongthong T, Boonarkart C, Phakaratsakul S, Suptawiwat O, Auewarakul P. Human Schlafen 11 inhibits influenza A virus production. Virus Res. 2023;334:199162. https:\/\/doi.org\/10.1016\/j.virusres.2023.199162.","journal-title":"Virus Res"},{"issue":"15","key":"3042_CR140","doi-asserted-by":"publisher","first-page":"e00104","DOI":"10.1128\/JVI.00104-19","volume":"93","author":"F Valdez","year":"2019","unstructured":"Valdez F, Salvador J, Palermo PM, Mohl JE, Hanley KA, Watts D, et al. Schlafen 11 restricts Flavivirus replication. J Virol. 2019;93(15):e00104\u201319. https:\/\/doi.org\/10.1128\/JVI.00104-19.","journal-title":"J Virol"},{"key":"3042_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1006066","volume":"12","author":"AC Stabell","year":"2016","unstructured":"Stabell AC, Hawkins J, Li M, Gao X, David M, Press WH, et al. Non-human primate Schlafen11 inhibits production of both host and viral proteins. PLoS Pathog. 2016;12:1\u201319. https:\/\/doi.org\/10.1371\/journal.ppat.1006066.","journal-title":"PLoS Pathog"},{"key":"3042_CR142","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1038\/s41467-022-33123-0","volume":"13","author":"FJ Metzner","year":"2022","unstructured":"Metzner FJ, Wenzl SJ, Kugler M, Krebs S, Hopfner K-P, Lammens K. Mechanistic understanding of human SLFN11. Nat Commun. 2022;13:5464. https:\/\/doi.org\/10.1038\/s41467-022-33123-0.","journal-title":"Nat Commun"},{"key":"3042_CR143","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10549-019-05313-w","volume":"177","author":"E Isnaldi","year":"2019","unstructured":"Isnaldi E, Ferraioli D, Ferrando L, Broh\u00e9e S, Ferrando F, Fregatti P, et al. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer. Breast Cancer Res Treat. 2019;177:335\u201343. https:\/\/doi.org\/10.1007\/s10549-019-05313-w.","journal-title":"Breast Cancer Res Treat"},{"key":"3042_CR144","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nature11433","volume":"491","author":"M Li","year":"2012","unstructured":"Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012;491:125\u20138. https:\/\/doi.org\/10.1038\/nature11433.","journal-title":"Nature"},{"key":"3042_CR145","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41594-018-0142-5","volume":"25","author":"M Li","year":"2018","unstructured":"Li M, Kao E, Malone D, Gao X, Wang JYJ, David M. DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs. Nat Struct Mol Biol. 2018;25:1047\u201358. https:\/\/doi.org\/10.1038\/s41594-018-0142-5.","journal-title":"Nat Struct Mol Biol"},{"key":"3042_CR146","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/cr.2012.155","volume":"23","author":"MR Jakobsen","year":"2013","unstructured":"Jakobsen MR, Mogensen TH, Paludan SR. Caught in translation: innate restriction of HIV mRNA translation by a schlafen family protein. Cell Res. 2013;23:320\u20132. https:\/\/doi.org\/10.1038\/cr.2012.155.","journal-title":"Cell Res"},{"key":"3042_CR147","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.chom.2021.07.006","volume":"29","author":"C Bou-Nader","year":"2021","unstructured":"Bou-Nader C, Muecksch F, Brown JB, Gordon JM, York A, Peng C, et al. HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. Cell Host Microbe. 2021;29:1421\u20131436.e7. https:\/\/doi.org\/10.1016\/j.chom.2021.07.006.","journal-title":"Cell Host Microbe"},{"key":"3042_CR148","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1172\/JCI44539","volume":"121","author":"H Chen","year":"2011","unstructured":"Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4\u2009+\u2009T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest. 2011;121:1549\u201360. https:\/\/doi.org\/10.1172\/JCI44539.","journal-title":"J Clin Invest"},{"key":"3042_CR149","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.4161\/cc.10.19.17051","volume":"10","author":"XG Yu","year":"2011","unstructured":"Yu XG, Lichterfeld M. Elite control of HIV: p21 (waf-1\/cip-1) at its best. Cell Cycle. 2011;10:3213\u20134. https:\/\/doi.org\/10.4161\/cc.10.19.17051.","journal-title":"Cell Cycle"},{"key":"3042_CR150","doi-asserted-by":"publisher","unstructured":"de Pablo A, Bogoi R, Bejarano I, Toro C, Valencia E, Moreno V et al. Short Communication: p21\/CDKN1A Expression Shows Broad Interindividual Diversity in a Subset of HIV-1 Elite Controllers. AIDS Res Hum Retroviruses [Internet]. 2015;32:232\u20136. Available from: https:\/\/doi.org\/10.1089\/aid.2015.0137.","DOI":"10.1089\/aid.2015.0137"},{"key":"3042_CR151","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.chom.2014.05.011","volume":"15","author":"J Leng","year":"2014","unstructured":"Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, et al. A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4\u2009+\u2009T cells from elite controllers. Cell Host Microbe. 2014;15:717\u201328. https:\/\/doi.org\/10.1016\/j.chom.2014.05.011.","journal-title":"Cell Host Microbe"},{"key":"3042_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01324-17","volume":"91","author":"JC Valle-Casuso","year":"2017","unstructured":"Valle-Casuso JC, Allouch A, David A, Lenzi GM, Studdard L, Barr\u00e9-Sinoussi F, et al. p21 restricts HIV-1 in Monocyte-Derived dendritic cells through the reduction of Deoxynucleoside triphosphate biosynthesis and regulation of SAMHD1 antiviral activity. J Virol. 2017;91:1\u201318. https:\/\/doi.org\/10.1128\/JVI.01324-17.","journal-title":"J Virol"},{"key":"3042_CR153","doi-asserted-by":"publisher","first-page":"E3997","DOI":"10.1073\/pnas.1306719110","volume":"110","author":"A Allouch","year":"2013","unstructured":"Allouch A, David A, Amie SM, Lahouassa H, Chartier L, Margottin-Goguet F, et al. p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A. 2013;110:E3997\u20134006. https:\/\/doi.org\/10.1073\/pnas.1306719110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3042_CR154","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1093\/jac\/dku276","volume":"69","author":"E Riveira-Mu\u00f1oz","year":"2014","unstructured":"Riveira-Mu\u00f1oz E, Ruiz A, Pauls E, Permanyer M, Badia R, Mothe B, et al. Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. J Antimicrob Chemother. 2014;69:3057\u201360. https:\/\/doi.org\/10.1093\/jac\/dku276.","journal-title":"J Antimicrob Chemother"},{"key":"3042_CR155","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15252\/embj.201796880","volume":"37","author":"P Mlcochova","year":"2018","unstructured":"Mlcochova P, Caswell SJ, Taylor IA, Towers GJ, Gupta RK. DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages. EMBO J. 2018;37:50\u201362. https:\/\/doi.org\/10.15252\/embj.201796880.","journal-title":"EMBO J"},{"key":"3042_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104750","volume":"299","author":"H Yang","year":"2023","unstructured":"Yang H, Espada CE, Phillips S, Martinez N, Kenney AD, Yount JS, et al. The host antiviral protein SAMHD1 suppresses NF-\u03baB activation by interacting with the IKK complex during inflammatory responses and viral infection. J Biol Chem. 2023;299:104750. https:\/\/doi.org\/10.1016\/j.jbc.2023.104750.","journal-title":"J Biol Chem"},{"key":"3042_CR157","doi-asserted-by":"publisher","unstructured":"Espada CE, Sari L, Cahill MP, Yang H, Phillips S, Martinez N et al. SAMHD1 impairs type I interferon induction through the MAVS, IKK\u03b5, and IRF7 signaling axis during viral infection. J Biol Chem. 2023;299:104925. https:\/\/doi.org\/10.1016\/j.jbc.2023.104925.","DOI":"10.1016\/j.jbc.2023.104925"},{"key":"3042_CR158","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1038\/s41467-021-24802-5","volume":"12","author":"C Martinat","year":"2021","unstructured":"Martinat C, Cormier A, Tobaly-Tapiero J, Palmic N, Casartelli N, Mahboubi B, et al. SUMOylation of SAMHD1 at lysine 595 is required for HIV-1 restriction in non-cycling cells. Nat Commun. 2021;12:4582. https:\/\/doi.org\/10.1038\/s41467-021-24802-5.","journal-title":"Nat Commun"},{"key":"3042_CR159","doi-asserted-by":"publisher","unstructured":"Bowen NE, Tao S, Cho Y-J, Schinazi RF, Kim B. Vpx requires active cellular dNTP biosynthesis to effectively counteract the anti-lentivirus activity of SAMHD1 in macrophages. J Biol Chem. 2023;299:104984. https:\/\/doi.org\/10.1016\/j.jbc.2023.104984.","DOI":"10.1016\/j.jbc.2023.104984"},{"key":"3042_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-023-00620-z","volume":"20","author":"M-HC Tsai","year":"2023","unstructured":"Tsai M-HC, Caswell SJ, Morris ER, Mann MC, Pennell S, Kelly G, et al. Attenuation of reverse transcriptase facilitates SAMHD1 restriction of HIV-1 in cycling cells. Retrovirology. 2023;20:5. https:\/\/doi.org\/10.1186\/s12977-023-00620-z.","journal-title":"Retrovirology"},{"key":"3042_CR161","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41564-022-01158-0","volume":"7","author":"N Tal","year":"2022","unstructured":"Tal N, Millman A, Stokar-Avihail A, Fedorenko T, Leavitt A, Melamed S, et al. Bacteria deplete deoxynucleotides to defend against bacteriophage infection. Nat Microbiol. 2022;7:1200\u20139. https:\/\/doi.org\/10.1038\/s41564-022-01158-0.","journal-title":"Nat Microbiol"},{"key":"3042_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007718","volume":"13","author":"N An","year":"2022","unstructured":"An N, Ge Q, Shao H, Li Q, Guo F, Liang C, et al. Interferon-inducible SAMHD1 restricts viral replication through downregulation of lipid synthesis. Front Immunol. 2022;13:1007718. https:\/\/doi.org\/10.3389\/fimmu.2022.1007718.","journal-title":"Front Immunol"},{"key":"3042_CR163","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1084\/jem.20072681","volume":"205","author":"R-P Sekaly","year":"2008","unstructured":"Sekaly R-P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205:7\u201312. https:\/\/doi.org\/10.1084\/jem.20072681.","journal-title":"J Exp Med"},{"key":"3042_CR164","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/COH.0b013e32833d17ac","volume":"5","author":"JH Kim","year":"2010","unstructured":"Kim JH, Rerks-Ngarm S, Excler J-L, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS. 2010;5:428\u201334. https:\/\/doi.org\/10.1097\/COH.0b013e32833d17ac.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR165","unstructured":"Bower R. Researchers halt HIV vaccine trial\u2013 what\u2019s the next step? AIDS Alert. 2008;23:8\u201310. https:\/\/www.clinician.com\/articles\/8993-researchers-halt-hiv-vaccine-trial-8212-what-s-the-next-step."},{"key":"3042_CR166","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coviro.2019.05.010","volume":"38","author":"C Lopez-Galindez","year":"2019","unstructured":"Lopez-Galindez C, Pernas M, Casado C, Olivares I, Lorenzo-Redondo R. Elite controllers and lessons learned for HIV-1 cure. Curr Opin Virol. 2019;38:31\u20136. https:\/\/doi.org\/10.1016\/j.coviro.2019.05.010.","journal-title":"Curr Opin Virol"},{"key":"3042_CR167","doi-asserted-by":"publisher","unstructured":"Shasha D, Walker BD. Lessons to be Learned from Natural Control of HIV \u2013 Future Directions, Therapeutic, and Preventive Implications. Front Immunol. 2013;4. https:\/\/doi.org\/10.3389\/fimmu.2013.00162.","DOI":"10.3389\/fimmu.2013.00162"},{"key":"3042_CR168","doi-asserted-by":"publisher","unstructured":"Yukselten Y, Wishah H, Li JA, Sutton RE. Targeting CCR5: A central approach to HIV treatment and cure strategies. Virology. 2025;603:110375. https:\/\/doi.org\/10.1016\/j.virol.2024.110375.","DOI":"10.1016\/j.virol.2024.110375"},{"key":"3042_CR169","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coviro.2015.06.007","volume":"14","author":"K Allers","year":"2015","unstructured":"Allers K, Schneider T. CCR5\u039432 mutation and HIV infection: basis for curative HIV therapy. Curr Opin Virol. 2015;14:24\u20139. https:\/\/doi.org\/10.1016\/j.coviro.2015.06.007.","journal-title":"Curr Opin Virol"},{"key":"3042_CR170","doi-asserted-by":"publisher","unstructured":"Wang J-W, Liu J-H, Xun J-J. CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions. Front Immunol [Internet]. 2025;18:16. https:\/\/doi.org\/10.3389\/fimmu.2025.1590690.","DOI":"10.3389\/fimmu.2025.1590690"},{"key":"3042_CR171","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1172\/JCI80566","volume":"126","author":"RB Jones","year":"2016","unstructured":"Jones RB, Walker BD. HIV-specific CD8\u2009+\u2009T cells and HIV eradication. J Clin Invest. 2016;126:455\u201363. https:\/\/doi.org\/10.1172\/JCI80566.","journal-title":"J Clin Invest"},{"key":"3042_CR172","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0000000000000965","volume":"20","author":"B Mothe","year":"2025","unstructured":"Mothe B, Brander C. Prospects for therapeutic T-cell vaccine strategies for HIV cure. Curr Opin HIV AIDS. 2025;20:463\u201371. https:\/\/doi.org\/10.1097\/COH.0000000000000965.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17481","author":"VR Arenas","year":"2023","unstructured":"Arenas VR, Rugeles MT, Perdomo-Celis F, Taborda N. Recent advances in CD8+T cell-based immune therapies for HIV cure. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17481.","journal-title":"Heliyon"},{"key":"3042_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10844","volume":"7","author":"T Bruel","year":"2016","unstructured":"Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016;7:10844. https:\/\/doi.org\/10.1038\/ncomms10844.","journal-title":"Nat Commun"},{"key":"3042_CR175","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000600","volume":"15","author":"M Caskey","year":"2020","unstructured":"Caskey M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin HIV AIDS. 2020;15:49\u201355. https:\/\/doi.org\/10.1097\/COH.0000000000000600.","journal-title":"Curr Opin HIV AIDS"},{"key":"3042_CR176","doi-asserted-by":"publisher","unstructured":"Mahomed S, Pillay K, Hassan-Moosa R, Galv\u00e3o BPGV, Burgers WA, Moore PL et al. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV \u2013 a review. AIDS Res Ther. 2025;22:44. https:\/\/doi.org\/10.1186\/s12981-025-00734-8.","DOI":"10.1186\/s12981-025-00734-8"},{"key":"3042_CR177","doi-asserted-by":"publisher","unstructured":"Murzin AI, Elfimov KA, Gashnikova NM. The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection. Pathogens. 2025;14:15. https:\/\/doi.org\/10.3390\/pathogens14010015.","DOI":"10.3390\/pathogens14010015"},{"key":"3042_CR178","doi-asserted-by":"publisher","unstructured":"Svensson JP. Targeting Epigenetics to Cure HIV-1: Lessons From (and for) Cancer Treatment. Front Cell Infect Microbiol. 2021;11:668637. https:\/\/doi.org\/10.3389\/fcimb.2021.668637.","DOI":"10.3389\/fcimb.2021.668637"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-03042-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:47:10Z","timestamp":1769518030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-025-03042-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-03042-9","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}